A Secondary Analysis of The N107C/CEC.3 (Alliance for Clinical Trials in Oncology/Canadian Cancer Trials Group) Randomized Clinical Trial When compared to WBRT, SRS alone resulted in less cognitive deterioration among long-term survivors. The link between late cognitive deterioration and WBRT was clinically significant. A significant decrease in cognition (2 SD) was linked to a decrease in overall QOL. WBRT, on the other hand, improved intracranial tumor control. This study provides detailed information about cognitive function in this patient population over time.

A Narrative Review Liquid biopsy is increasingly being used clinically in advanced lung cancer, according to this review, and ongoing research is identifying applications of circulating tumor DNA-based testing that complement tissue analysis across a wide range of clinical settings. At many stages of the patient’s oncologic journey, circulating tumor DNA technologies are demonstrating potential benefits for patients, health care practitioners, health care systems, and researchers.

Lauren C. Pinter-Brown, MD, the Health Sciences Professor of Medicine and Dermatology at the Chao Family Comprehensive Cancer Center at the University of California, Irvine, discusses the most common types of T-cell lymphoma, recent changes to its diagnosis and classification, standard approaches, treatment challenges, unmet needs, new treatments, promising areas of research, and other recommendations regarding its management.

A cohort study of 1,024 patients at an urban academic medical center discovered that 13% of oral anticancer drug prescriptions were never filled. The most common reason for failure to receive an oral anticancer drug prescription was due to patient and clinician decision-making; 13% of cases of failure to receive an oral anticancer drug prescription were directly associated with financial access issues.

Cediranib plus olaparib improved rPFS in men with mCRPC compared to olaparib alone. This combination was linked to an increase in the occurrence of grade 3-4 adverse events. BRCA2-mutated subgroups receiving olaparib with or without cediranib had a numerically longer median rPFS.

The researchers believe these are the first data to compare FGFR-directed therapy with chemotherapy in patients with FGFR-altered UC, demonstrating comparable efficacy and manageable safety. Experimentation revealed that FGFR3 DNA alterations in conjunction with FGFR1/3 mRNA overexpression may be better predictors of rogaratinib response.